MedTrace Logo

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

NCT06094790 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-10-23

No results posted yet for this study

Summary

A study designed to characterize the plasma pharmacokinetic (PK) profile of CORT125134 in healthy subjects receiving once-daily oral administration of the current capsule formulation of CORT125134 for 14 days.

Conditions

  • Healthy

Interventions

DRUG

CORT125134 150 mg

CORT125134 150 mg (3 X 50 mg current capsule formulation)

DRUG

CORT125134 250 mg

CORT125134 250 mg (5 X 50 mg current capsule formulation)

DRUG

CORT125134 dose to be determined

CORT125134 current capsule formulation, dose to be determined

Sponsors & Collaborators

  • Corcept Therapeutics

    lead INDUSTRY

Principal Investigators

  • Andreas Moraitis · Corcept Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-18
Primary Completion
2017-11-15
Completion
2017-11-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06094790 on ClinicalTrials.gov